Solural Pharma has developed an oral chemotheraphy product that replaces current marketed intravenous product. Solural Pharma has a strong expertise in development of improved oral formulations. Solural Pharma has development capabilities on their own, or together with partners and CROs to develop new oral formulations, from concept idea until clinical proof of concept.
Solural Pharma has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. Solural Pharma is one of more than 500 companies that Accelerace already have accelerated.